Safety & Monitoring
Universal safety context, bloodwork concepts, monitoring considerations, and life-stage factors relevant across the Compound Research Library.
Use this page as an educational reference, not as individualized medical advice. Laboratory results, monitoring decisions, contraindications, and treatment choices should be reviewed with a qualified clinician.
Universal safety
These general safety considerations apply across injectable compounds. Each compound profile may also include additional contraindications, warnings, interactions, monitoring considerations, and stop criteria.
Evidence level
Do not assume a compound has completed human trials unless its profile specifically states that evidence exists. Many research protocols rely on animal data, limited clinical evidence, or community-derived practices, and product quality can vary.
General contraindications
Common contraindication themes include hypersensitivity, active systemic or injection-site infection, pregnancy or lactation unless specifically indicated and clinician-supervised, and pediatric use unless specifically indicated.
Urgent stop signals
Anaphylaxis, serious injection-site infection, or new unexplained symptoms are reasons to stop and seek appropriate medical care.
Handling & baseline context
Safe handling includes aseptic technique, single-use sterile needles, appropriate sharps disposal, respecting cold-chain and storage limits, marking first-puncture dates, inspecting solutions before use, and rotating injection sites. Common baseline laboratory concepts include CBC, CMP/BMP, HbA1c when relevant, lipids, TSH, and pregnancy testing where applicable.
These are general reference concepts, not individualized testing or treatment instructions. Reference intervals vary by laboratory, population, medications, and clinical context.
Understanding your bloodwork
The ranges below are adult-oriented reference points intended to make common markers easier to understand. Always compare results with the range printed by the laboratory and interpret them in the appropriate clinical context.
| Marker | Reference range | Why it matters |
|---|---|---|
| IGF-1 | Age-dependent; reference range: ~200–400 ng/mL in 20s declining to ~70–180 at 70+ | Tracks growth signaling; interpret with age-based interpretation. |
| Fasting glucose | 70–99 mg/dL | Blood glucose after an overnight fast; values of 100–125 as prediabetes and ≥126 as diabetes thresholds. |
| HbA1c | <5.7% | Approximate 3-month glucose average; reference range: 5.7–6.4% as prediabetes and ≥6.5% as diabetes thresholds. |
| eGFR | ≥60 mL/min/1.73m² | Estimate of kidney filtration; interpret using trend and hydration context. |
| Total testosterone — men | 300–1000 ng/dL | Adult male reference band shown here. |
| Estradiol — men | 10–40 pg/mL | Adult male estradiol reference band. |
| Prolactin | Men 4–15; women 4–23 ng/mL | Pituitary hormone; some GH secretagogues can raise prolactin. |
| Hematocrit | Men 41–53%; women 36–46% | Percentage of blood composed of red cells; values of >54% as high-risk. |
| TSH | 0.4–4.5 mIU/L | Pituitary signal used to assess thyroid regulation. |
| LDL cholesterol | <100 mg/dL optimal | LDL is a commonly used cardiovascular-risk marker. |
| B12 | 200–900 pg/mL; target shown here: 400+ | Vitamin important to neurologic and red-cell function. |
| Vitamin D (25-OH) | 30–100 ng/mL; source aims 40–60 | Adult-oriented reference range for 25-OH vitamin D. |
| hsCRP | <3 mg/L | Nonspecific marker of background inflammation. |
Women’s reproductive panel
Cycle timing can substantially change reproductive hormone results, and testosterone testing in men is typically interpreted in the context of time of day. The ranges below are general reference values, not diagnostic cutoffs for an individual.
| Marker | Reference range | Context |
|---|---|---|
| Total testosterone | 8–60 ng/dL | Higher values can be associated with PCOS. |
| Estradiol (E2) | Follicular 20–150; mid-cycle 150–750; luteal 30–450; postmenopause <30 pg/mL | Cycle phase changes interpretation. |
| LH / FSH | LH follicular 2–12, surge 20–100; FSH follicular 3–10; menopause >25 mIU/mL | Used in reproductive context. |
| Progesterone | Follicular 3–5 ng/mL | Luteal progesterone can be used as an ovulation marker. |
| SHBG | Women 18–144; men 10–57 nmol/L | Varies with metabolic and estrogen context. |
| Pregnancy (β-hCG) | Negative where required | Pregnancy status should be considered before compounds with pregnancy-related contraindications. |
Sex & life-stage considerations
Growth-hormone axis
GH-to-IGF-1 response can differ by sex, and oral estrogen can affect IGF-1 interpretation.
Laboratory response should be interpreted in the context of sex, age, and hormone use rather than assuming identical responses.
Weight-loss / incretin research
Side-effect and reproductive considerations can differ between women and men.
Pregnancy potential and contraception are important considerations when evaluating relevant compounds.
Reproductive & hormonal research
Still cycling, perimenopause, postmenopause, younger men wanting fertility, and older men are treated as distinct contexts.
Bloodwork, appropriate screening, and clinician involvement become increasingly important when reproductive or hormonal factors are involved.
How references are weighted
Not all evidence carries the same weight. Regulatory documents, clinical studies, trial registries, and other primary medical sources provide stronger support than protocol databases, clinic material, or community reports. Community-derived information is most relevant where formal clinical data are limited and should not be treated as equivalent to established clinical evidence.
